BioSpace News Archive

GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announces the Company’s strategy for bringing its pipeline product nabiximols to the U.S. market.

Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the appointments of John Lewicki, PhD, as Chief Scientific Officer, and Ann Kapoun, PhD, as Senior Vice President of Translational Research and Development.

BeyondSpring Inc. announced that the Company presented clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine.

Centene Corporation announced that its Illinois subsidiary, Meridian Health Plan of Illinois, Inc., and NextLevel Health Partners, Inc., a health plan serving Medicaid members in Cook County, Illinois, have entered into a Member Transfer Agreement.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that the final data analysis from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis has been completed.

Athletico Physical Therapy waives Co-payments and Co-insurance for First Responders and Licensed Health Care Professionals Diagnosed with COVID-19

Flagship Biosciences, providers of expert tissue data insights, today announced the launch of a new clinical diagnostics immuno-oncology service, TissueInsight.

Company’s first biologic license application candidate TTAX01 to enter Investigational New Drug Phase 3 Trials for Diabetic Foot Ulcer indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs

Skin cancer is the most common cancer in the U.S., and nearly 20 Americans die from melanoma, the deadliest form of skin cancer, every day.